Amneal Pharmaceuticals (NASDAQ:AMRX) Announces Quarterly Earnings Results

Amneal Pharmaceuticals (NASDAQ:AMRX) released its quarterly earnings results on Tuesday. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.23 by $0.03, FiscalAI reports. The firm had revenue of $862.68 million during the quarter. Amneal Pharmaceuticals had a net margin of 4.17% and a return on equity of 283.50%.

Here are the key takeaways from Amneal Pharmaceuticals’ conference call:

• Strong Q3 performance: Revenue rose 10% to $863 million, adjusted EBITDA increased 30% to $207 million, and adjusted EPS grew 53% to $0.26, prompting Amneal to raise its 2026 revenue, EBITDA, and EPS guidance.
• Affordable medicines revenue increased 19% to $547 million, supported by women’s health transdermal patches, new product launches, and biosimilar orders. The recently launched lanreotide generated approximately $7 million in late-September sales, with management expecting substantially higher revenue in Q4 and targeting 30%–40% market share.
• The completed Kashiv acquisition gives Amneal integrated biosimilar development, manufacturing, and commercialization capabilities. Management expects $400 million–$500 million of financial benefits over time and recently secured $60 million in New Jersey tax credits tied largely to biosimilar-related expansion.
• Specialty products continued to gain momentum, with CREXONT adding approximately 400 prescribers monthly and BREKIYA tracking ahead of expectations. Management expressed confidence that both products could reach the middle to high end of its long-term outlook.
• Operating cash flow guidance was reduced by $25 million at the midpoint to $325 million–$375 million because Amneal is building finished-goods inventory to meet demand and expects some collections to shift into Q1 2027. Net leverage was 3.0 times adjusted EBITDA after the Kashiv acquisition, with year-end leverage expected to rise to 3.6 times.

Amneal Pharmaceuticals Stock Up 2.2%

AMRX stock traded up $0.45 during trading on Thursday, hitting $20.40. 86,733 shares of the company’s stock traded hands, compared to its average volume of 2,424,069. The company has a quick ratio of 1.44, a current ratio of 1.87 and a debt-to-equity ratio of 5.61. The firm has a market capitalization of $6.51 billion, a P/E ratio of 48.67, a PEG ratio of 2.36 and a beta of 1.24. Amneal Pharmaceuticals has a 1 year low of $11.29 and a 1 year high of $21.68. The business has a fifty day simple moving average of $19.26 and a two-hundred day simple moving average of $15.85.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director John Kiely sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $17.64, for a total value of $882,000.00. Following the transaction, the director directly owned 210,252 shares of the company’s stock, valued at approximately $3,708,845.28. The trade was a 19.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jason Daly sold 210,000 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total value of $3,654,000.00. Following the transaction, the executive vice president directly owned 35,171 shares in the company, valued at $611,975.40. This represents a 85.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 413,016 shares of company stock valued at $7,216,567 over the last 90 days. Insiders own 17.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on AMRX shares. Piper Sandler reaffirmed an “overweight” rating and set a $21.00 price objective on shares of Amneal Pharmaceuticals in a research report on Wednesday. Leerink Partners began coverage on Amneal Pharmaceuticals in a report on Wednesday, September 9th. They issued an “outperform” rating and a $23.00 target price on the stock. Weiss Ratings raised shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Barclays upped their price objective on Amneal Pharmaceuticals from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday, September 17th. Finally, JPMorgan Chase & Co. raised their target price on shares of Amneal Pharmaceuticals from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.75.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.